---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-025438"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:53:02.093112+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eton Q2 product sales $18.9M (+108% YoY); non-GAAP EPS $0.03; raises revenue run-rate guidance

## Summary
- Q2 product sales $18.9M, up 108% YoY; GAAP EPS $(0.10), non-GAAP EPS $0.03.
- Adjusted EBITDA $3.1M vs ($1.6M) prior year; adjusted gross margin improved to 75%.
- Launched KHINDIVI (hydrocortisone oral solution) in June; INCRELEX reached 100 active patients ahead of year-end guidance.
- Company projects $80M annual revenue run rate in Q3, one quarter ahead of prior outlook.
- ET-600 NDA accepted with PDUFA date Feb 25, 2026; second patent granted.

## SEC filing metadata
- accession: 0001437749-25-025438
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774925025438/0001437749-25-025438-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774925025438/eton20250802_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-025438
- JSON: https://secwatch.observer/filing/0001437749-25-025438.json
- Plain text: https://secwatch.observer/filing/0001437749-25-025438.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.